TY - JOUR T1 - Nomogram to predict the presence of <em>EGFR</em> activating mutation in lung adenocarcinoma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/09031936.00010111 SP - erj00101-2011 AU - N. Girard AU - C.S. Sima AU - D.M. Jackman AU - L.V. Sequist AU - H. Chen AU - J.C-H. Yang AU - H. JI AU - B. Waltman AU - R. Rosell AU - M. Taron AU - M.F. Zakowski AU - M. Ladanyi AU - G. Riely AU - W. Pao Y1 - 2011/01/01 UR - http://erj.ersjournals.com/content/early/2011/07/12/09031936.00010111.abstract N2 - EGFR tumour genotyping is crucial to guide treatment decisions regarding the use of EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). However, some patients may not be able to obtain tumour testing, either because tissue is limited and/or tests are not routinely offered. Here, we aimed at building a model-based nomogram to allow for prediction of the presence of EGFR mutations in NSCLC.We retrospectively collected clinical and pathological data on 3006 patients with NSCLC who had their tumours genotyped for EGFR mutations at 5 institutions worldwide. Variables of interest were integrated in a multivariate logistic regression model.In the 2392 non-Asian patients with lung adenocarcinomas, the most important predictors of harboring EGFR mutation were: lower tobacco smoking exposure (OR=0.41,95%CI:0.37–0.46), longer time interval between smoking cessation and diagnosis (OR=2.19,95%CI:1.71–2.80), advanced stage (OR=1.58,95%CI:1.18–2.13), and papillary (OR=4.57,95%CI:3.14–6.66) or bronchiolo-alveolar (OR=2.84,95%CI:1.98–4.06) histologic predominant subtype. A nomogram was established and showed excellent discriminating accuracy: concordance index on an independent validation dataset was 0.84.As clinical practices transition to incorporating genotyping as part of routine care, this nomogram could be highly useful to predict the presence of EGFR mutations in lung adenocarcinoma in non-Asian patients when mutational profiling is not available or possible. ER -